thyroidism in CAPD patients despite higher peak levels of 1,25(OH ) 2 -vitamin D with pulse therapy. Background. Calcitriol therapy is the mainstay of therapy for the treatment of secondary hyperparathyKey words: calcitriol; calcium balance; CAPD; dialysis; roidism. Oral administration of calcitriol is necessary hyperparathyroidism; renal osteodystrophy in CAPD patients, but no studies have directly compared different routes of administration in this patient population.
level (pulse therapy) is more important than the total delivered dose, we randomized CAPD patients with Bone disease is a common cause of morbidity in mild to moderate secondary hyperparathyroidism to patients with chronic renal failure undergoing dialytic receive either pulse (3.0 mg twice a week, n=10) or therapy. In patients receiving continuous ambulatory daily (0.75 mg a day, n=8) oral calcitriol in comparable peritoneal dialysis (CAPD), osteitis fibrosa cystica due weekly doses. The main comparison was the rate of to secondary hyperparathyroidism is the histological decline of serum intact parathyroid hormone (PTH ) finding in 13 to 66% of biopsies [1, 2] . One of the most levels to reach the desired end-point of 100 pg/ml. The effective and physiological methods of reducing serum patients were dialysed with low-calcium dialysate and parathyroid hormone concentration (PTH ) is treatreceived only calcium-containing phosphate binders. ment with calcitriol, which directly inhibits the tranResults. Pharmacokinetic analysis after a single dose scription of pre-pro-PTH [3] and normalizes bone of 3.0 mg (pulse) vs 0.75 mg (daily) revealed 1,25(OH ) 2 -histology [4, 5] . Initially, calcitriol administered orally vitamin D levels to be higher in the pulse group at 3 was utilized for the treatment of secondary hyperparaand 6 h, but equivalent by 12 h. The area under the thyroidism [6-8]. However, hypercalcaemia was curve for 1 week of daily and 1 week of pulse therapy common, presumably because of the direct action of was equal. The patients in the 2 arms had equivalent calcitriol on the gastrointestinal absorption of calcium basal serum levels of PTH (pulse=562±291 vs daily= [9] . To overcome this effect, the intravenous adminis-454±113 pg/ml ), calcium (pulse=2.32±0.20 vs tration of calcitriol became widely utilized for the daily=2.32±0.12 mmol/l ) and phosphorus (pulse= treatment of secondary hyperparathyroidism in haemo-1.32±0.52 vs daily=1.35±0.26 mmol/l ). The time dialysis patients [11] [12] [13] . In addition to the relative required for the PTH to decrease to 100 pg/ml and the decrease in calcium absorption from the gut, the intrarate of decline in PTH were similar (time: pulse= venous administration of calcitriol had the theoretical 14.2±6.8 weeks, daily=12.2±7 weeks; rate: pulse= advantage of higher peak serum levels, providing 7.4±4.2 vs daily=8.4±4.2% PTH/week; P=NS ). The enhanced end-organ effect at the level of the paraserum calcium increased similarly in both groups.
thyroid gland. However, recent randomized controlled Hypercalcaemia (>2.9 mmol/l ) was rare (pulse=3, trials have demonstrated that intravenous and oral daily=2 episodes).
calcitriol given in thrice weekly 'pulse' doses are equally Conclusions. This study demonstrates that pulse and efficacious for the treatment of secondary hyperparadaily calcitriol are similarly effective and safe for the thyroidism in haemodialysis patients, despite greater treatment of mild to moderate secondary hyperparapeak serum levels with the intravenous formulation [14] [15] [16] . In CAPD patients, the intravenous administration orally one to three times per week. The pulse calcitriol pulse dose was chosen to provide a similar total weekly dose effectively suppressed PTH, but hypercalcaemia was as the daily therapy. Given the limitation of available tablet common [22] [23] [24] [25] . However, no direct comparisons of sizes, the weekly dose was 5.25 mg for the daily arm and 6 mg the pulse administration of calcitriol with the daily for the pulse arm. Patients in the daily arm were started on administration of calcitriol has been performed in 0.25 mg daily with the dose increased by 0.25 mg per day CAPD patients. CAPD patients may be at a greater every 2 weeks, until the maximum dose of 0.75 mg was risk for hypercalcaemia than haemodialysis patients achieved. Patients in the pulse arm were started on 1.0 mg because of the greater overall positive calcium balance administered twice weekly, with the dose increased by 1.0 mg [26 ] , and therefore alternatives to the pulse regimen per dose every 2 weeks, until the maximum dose of 3.0 mg twice weekly was achieved. Thus the maximum dose in each are needed. The purpose of the present study was (1) arm was begun on week 4 for all patients. All patients to determine whether pulse calcitriol is superior to received the same lot number of RocaltrolA (provided by daily calcitriol for the treatment of secondary hyperRoche Laboratories, Nutley, NJ ). The dose was continued parathyroidism when given in comparable weekly oral until the study end-point of an intact PTH of 100 pg/ml was doses, and (2) to determine the safety of oral calcitriol achieved. Compliance was monitored by tablet counts at in CAPD patients when used in conjunction with low-each clinic visit, with a count discrepancy of >10% on two calcium dialysate. The pharmacokinetics of the pulse visits criteria for removal from the study. Upon completion and daily regimens were compared to determine the of the study, the patients answered a questionnaire as to effect of peak serum levels vs total serum levels on the their preference of the frequency of administration. suppression of PTH. In addition the effect of the two
Beginning at least 4 weeks prior to the administration of calcitriol, each patient was switched to a low-calcium regimens on calcium balance was evaluated.
(1.25 mmol/l ) dialysate and calcium acetate as a phosphate binder. The dose of calcium acetate was adjusted as needed to keep the serum phosphorus below 1.94 mmol/l. If patients
Subjects and methods
could not tolerate calcium acetate, they were switched to calcium carbonate. The mean elemental calcium content of
Patient selection
the calcium-containing phosphate binders were calculated at each clinic visit. To confirm a steady state, at least two All patients undergoing CAPD at Indiana University subsequent serum determinations for calcium, phosphorus Hospital or Richard L. Roudebush Veterans Administration and PTH concentration were done after these changes and Hospital between January 1993 and January 1995 and willing before enrollment. Patients were counselled on a standard to give informed consent were eligible. The study was renal diet of 800 mg phosphorus, 2 g sodium, 3 g potassium, approved by the Institutional Review Board at each hospital. 1.2 g/kg protein diet by renal dietitians. The patients comInclusion criteria were age greater than 18 years, on CAPD pleted a 3-day food diary at baseline and at 3 months, and for at least 3 months, and secondary hyperparathyroidism. a monthly food frequency survey. The latter was defined by an intact PTH of at least 200 pg/ml All values for calcium were corrected to a normal serum (normal up to 65 pg/ml ) that was stable or rising since the albumin of 35 g/l ( lower limit of normal for our hospital ) initiation of CAPD, together with an elevated serum total based on the patient's albumin. If hypercalcaemia (defined alkaline phosphatase concentration and/or radiographic as serum calcium >2.9 mmol/l [6,7]) developed, the dose of evidence of subperiosteal bone resorption. Aluminium-calcitriol was withheld for 3 days. The serum calcium was associated bone disease was excluded by a desferrioxamine repeated, and if ∏2.9 mmol/l, and the calcium×phosphorus (DFO) stimulation test with a delta serum aluminium of less product <70, the calcitriol was restarted at the previous than 3700 nmol/l in any patient with a history of ingestion dose and the dose of calcium containing phosphate binder of aluminium-containing medications. Patients were also was reduced. If hypercalcaemia >2.9 mmol/l occurred on excluded if they had a serum calcium concentration persist-two consecutive determinations, the calcitriol was withheld ently greater than 2.5 mmol/l or serum phosphorus concen-until the calcium concentration normalized and the calcitriol tration persistently greater than 2.3 mmol/l, were currently was restarted at a dosage 0.25 mg less per day for the daily receiving medications known to interfere with vitamin D dose or 1.0 mg less per dose for the pulse arm. If hyperphosmetabolism or bone turnover such as steroids or anticonvuls-phataemia (defined as serum phosphorus greater than ants, or were non-compliant with dialysis prescription.
2.3 mmol/l ) or a calcium×phosphorus product of >70 Of the 120 CAPD patients screened for enrollment, 42 developed, 30 cc of aluminium hydroxide was given with patients had an elevated serum PTH concentration. Of these, each meal for 3 days. The serum calcium and phosphorus 25 met all the inclusion/exclusion criteria. Four patients was repeated and if the phosphorus was ∏2.3 mmol/l and refused the study, the other 21 were enrolled. One of these the product <70, the aluminium was discontinued and the patients decided not to complete the study after only 2 weeks calcium binder restarted at a higher dose. for personal reasons and her position was re-randomized.
Serum samples were taken at baseline, 2, 4, 6, 8, 12, 16, All calcitriol supplements were stopped at least 1 month 20 and 24 weeks, drawn 12-18 h after the last dose of either prior to the start of the study.
daily or pulse calcitriol. The serum was collected and frozen at −70°C until assayed. Serum was analysed for chem-17 and CBC at baseline, 1,25(OH ) 2 -vitamin D, PTH, calcium,
Study design
phosphorus, albumin, and alkaline phosphatase at each time point, and tartrate-resistant alkaline phosphatase and osteoPatients were randomized by random number generation to calcin every 4 weeks. The chem-17, calcium, albumin, phosreceive oral calcitriol administered in a once daily (0.75 mg phorus, and total alkaline phosphatase were measured on a /day) dose vs a twice weekly pulse (3.0 mg) dose, taken Roche MIRA autoanalyser. The intact PTH was assayed approximately 3 h after the evening meal. The dose of the daily oral therapy was chosen to be comparable to the dose utilizing an immunoradiometric assay (Nichols Institute, Los Angeles, CA). Serum 1,25(OH ) 2 -vitamin D was quantified markers of bone metabolism. Patient preferences in the exit survey were compared using Fisher's Exact test. All analysis by competitive protein binding assay as previously described utilizing vitamin D cytosolic receptor from calf thymus were done with SPSS (SPSS 6.1 for Windows, SPSS, Inc., Chicago, IL 1994) and results are expressed as mean±SD. following purification by HPLC [27] . Bound and free sterol separation was achieved by charcoal/dextran after incubation. The intra-assay coefficient of variation is less than 10% for all assays with the exception of osteocalcin where the Results intra-assay coefficient of variation is 16%.
Twenty-one patients were enrolled in the study. Three Total body calcium and bone densitometry studies patients did not complete the study: one received a transplant at 8 weeks (pulse), one underwent surgery To determine the effect of calcitriol administration in con-and could not take oral medications for a prolonged junction with calcium-containing phosphate binders and low-period at 10 weeks (daily), and a third patient was calcium dialysate on calcium balance, bone densitometry and non-compliant with erroneous pill counts and no rise total body calcium were measured in patients who agreed, in calcitriol levels and was dropped from the study at at baseline and at the end of the study. Bone densitometry 16 weeks (daily). Eighteen patients completed the of the hip, lumbar spine, and radius, and total body calcium study, 10 in the pulse group and 8 in the daily group.
were measured by dual-energy X-ray absorptiometry The patient characteristics are described in Table 1 the baseline biochaemical values in Table 2 . There was no difference between the two groups in baseline demographic or biochemical parameters. Inclusion of Pharmacokinetic studies the three patients who were randomized but did not complete the study did not alter these characteristics.
Prior to initiating therapy with calcitriol, patients were admitted to the General Clinical Research Center for pharm-Eight patients were changed from a 1.75-mmol/l to a acokinetic and calcium balance studies. Values are expressed as mean±standard deviation. There were no significant differences in any of the variables between the two groups. normal 0.7±0.8). The osteoid surface was similarly elevated (26.7±16.1%, range 11.8-60.1 compared to normal value of 14.5±8.2), although the osteoid width was not increased in any patient. Only one patient had evidence of aluminium staining, but this was less than 4%. These results are consistent with mild osteitis fibrosa. Thus, in those patients who underwent baseline bone biopsy, the biochemical and radiographic inclusion criteria correlated well with bone histology. Five of the patients also underwent biopsy at the end of the study, but comparative histomorphometry was not possible. However, there was qualitative improvement in all five biopsies.
Because of the variable initial PTH concentrations Fig. 1 . Individual response to calcitriol therapy. Intact PTH concenand differing time to the stated end-point PTH concen-tration vs weeks in patients treated with the pulse regimen (closed tration of 100 pg/ml, the decline in PTH was expressed circles, dashed line, 3.0 mg twice weekly, n=10) or daily regimen (open squares, solid line, 0.75 mg twice weekly, n=8) until the as % change PTH/time, as described in the methods. desired end-point of a serum PTH concentration of 100 pg/ml The % change PTH/time was 7.4±4.2%/week in the was achieved.
pulse group and 8.4±4.2%/week in the daily group (P=NS ). The weeks of calcitriol therapy required to reach the PTH end-point of 100 pg/ml was not different between the two groups (pulse=14.2±6.8 weeks, groups (pulse=1.74±0.48 to 1.68±0.58 mmol/l; daily=1.74±0.48 to 1.52±0.29 mmol/l, P=NS). daily=12.2±7.0 weeks), and both groups had similar PTH value at end-point (pulse=86.9±24.7 pg/ml, Hypercalcaemia (>2.9 mmol/l ), requiring holding the calcitriol for 3 days, occurred three times in the pulse daily=90.2±32.3 pg/ml ). The response of each patient is shown in Figure 1 . Analysis of these results indicate group (three different patients, or 3/65 (4.6%) determinations) and twice in the daily group (1 patient, or that it would require 277 subjects per group to have 80% power to find a difference of this magnitude at 2/47 (4.2%) determinations). All of these episodes of hypercalcaemia >2.9 mmol/l occurred at the end-point the 0.05 significance level, suggesting that our inability to find a difference reflects a true lack of difference or the visit before the end-point, and all were associated with a PTH concentration of <150 pg/ml. Twelve in therapy.
The corrected serum calcium increased similarly in other episodes of mild hypercalcaemia (>2.6 mmol/l, the upper limit of normal for assay) occurred seven both groups from baseline to end-point. The corrected serum calcium increased from 2.32±0.20 to times in the pulse group (four different patients) and six times in the daily group (four different patients). 2.59±0.25 mmol/l in the pulse group and 2.32±0.12 to 2.65±0.30 mmol/l in the daily group (P<0.01, One of these patients was given aluminium hydroxide for 3 days for an elevated calcium×phosphorus prodbaseline vs end-point). The mean change in corrected calcium ((calcium at end-point-calcium at start)/weeks uct, but all the other episodes of mild hypercalcaemia occurred in the presence of a calcium×phosphorus to endpoint) was 0.025±0.022 in the pulse group and 0.037±0.027 mmol/l/weeks in the daily group product <70. No other patients required aluminiumcontaining phosphate binders, and no episodes of (P=NS ). The serum phosphorus was not altered during the course of the study and similar in both hyperphosphataemia (>2.3 mmol/l ) were observed.
Thus, no calcitriol dose reduction was required in any patient.
There was no difference in the monthly dietary calcium or phosphorus intake, or the elemental calcium content of phosphorus binders between the two groups ( Table 2) , nor was there a change during the study (data not shown). No patient showed evidence of protein-calorie malnutrition by food diaries. There was no correlation between the serum calcium, phosphorus, alkaline phosphatase, and 1,25(OH )-vitamin D serum levels and % change PTH/time. However, there was a correlation between the calcium and simultaneous PTH values (P<0.001, r=−0.30). There was no change in the serum osteocalcin or tartrate acid phosphatase during the course of the study and no levels at 3 and 6 h in the pulse group compared to the daily group (3 h, pulse=72.9±24.7 pg/ml, a greater rise observed in the pulse group (18.0±9.6 daily 31.7±12.9 pg/ml; 6 h, pulse=63.8±20.2 pg/ml, to 85.1±49.9 pg/ml in the pulse group and 19.7±14.6 daily=37.9±8.5 pg/ml; both P<0.05, Figure 2) . to 42.5±13.7 pg/ml, P<0.05 for comparison between There was no statistical difference in the calcitriol levels pulse and daily, P<0.02 for comparison between baseat 24 h, but the level was still above baseline in both line and end-point). The maximum 1,25(OH ) 2 -vitamin groups, indicating a nadir had not yet been reached. D level achieved by each patient was also greater in Thus the true area under the curve could not be the pulse group (76.9±19.2 pg/ml ) compared to the determined. However, in pharmacokinetic studies of 1 daily group (48.3±16.3 pg/ml, P<0.05). Therefore, week duration in a single patient, the area under the despite greater peak serum levels in the pulse group curve was equivalent in the pulse vs daily route of compared to the daily group, PTH was equally supadministration (36 vs 35 ng/ml/week; Figure 3) . The
pressed. An exit interview indicated patients had no serum 1,25(OH ) 2 -vitamin D level increased significpreference of pulse vs daily routes of administration. antly in both groups from baseline to end-point with
The total body calcium measured by DEXA increased similarly in both groups (pulse=2956±791 to 3060±788 g, n=7; daily=2868±518 to 2913± 550 g, n=5; P<0.04, baseline compared to end-point for each group). Unfortunately these studies do not differentiate soft-tissue from bone calcium. However, bone densitometry of hips, spine, and radius were unchanged in both groups.
Discussion
The results of this randomized study demonstrate that the pulse and daily routes of administration of calcitriol, when administered in comparable total weekly doses are similarly efficacious in suppressing PTH in patients on CAPD. There was no difference in dietary calcitriol in the pulse regimen. To minimize the incid-ence of hypercalcaemia, the calcitriol was administered In CAPD patients the intravenous use of calcitriol is impractical. Martin et al. [19] first utilized pulse oral at night and low-calcium dialysate was utilized. As a result, hypercalcaemia was a rare finding compared to calcitriol in five CAPD patients, administering 5 mg calcitriol orally, twice weekly. They demonstrated a previous studies [22] [23] [24] [25] . Positive calcium balance was achieved despite the low-calcium dialysate. These 60% decline in serum PTH after 6 weeks of therapy, but hypercalcaemia required a dose reduction to 3 mg results demonstrate, for the first time in CAPD patients, that the total amount of calcitriol adminis-in one patient. Juergensen et al. [23] found oral calcitriol to be effective in the suppression of PTH in 38 of tered is more important than the peak serum levels in suppressing PTH secretion. Furthermore, not only is 43 CAPD patients studied, administering 5 mg calcitriol twice weekly for 1 year. However, hypercalcaemia was daily and pulse calcitriol efficacious in CAPD patients for the treatment of secondary hyperparathyroidism, a problem in six patients, and several required aluminium-containing phosphate binders [23] . Scanziani but, when administered at night in conjunction with a low-calcium dialysate, is a safe therapy at doses previ-et al. [22] followed 19 CAPD patients for 18 months, utilizing 0.5-4.0 mg three times weekly (mean maximum ously found to cause hypercalcaemia. These results confirm those found by Herrmann et al. in a similar dose 1.21±1.53 mg/dose). In order to control hypercalcaemia, patients required the use of magnesiumstudy of haemodialysis patients, but with less frequent hypercalcaemia and hyperphosphataemia [21] .
containing phosphate binders, and five patients required the use of dialysate containing no calcium The initial studies evaluating oral calcitriol therapy were in HD patients. These studies found [22] . Hypercalcaemia was an even greater problem in a study of 15 CAPD patients given only 0.5 mg twice 0.5-1.0 mg/day of oral calcitriol effective in decreasing the serum PTH, but one-third to one-half of patients weekly for 8 weeks [24] . These patients had a significant increase in their serum calcium and had at least one episode of hypercalcaemia (>2.9 mmol/l; [6, 7] ). In paediatric CAPD patients, calcium×phosphorus product despite a pulse dose of only 0.5 mg twice weekly. The high incidence of hyperoral calcitriol (mean dose 0.61±0.37 mg /day) significantly decreased the serum PTH after 12 months of calcaemia probably reflected the inclusion of patients with previous hypercalcaemia in response to vitamin treatment but 18 episodes of hypercalcaemia occurred in 11 patients [8] . The frequent occurrence of hypercal-D therapy [24] .
In the present study we found a low incidence of caemia prompted the study of other administrative routes. Slatapolsky et al. first demonstrated the effect-hypercalcaemia in both the pulse and daily calcitriol groups even with the exclusive use of calciumiveness of up to 4.0 mg of calcitriol given intravenously thrice weekly to haemodialysis patients in lowering containing phosphate binders. The serum calcium levels were measured within 18 h of administration serum PTH [11], and Andress et al. demonstrated coincident improvement in bone histology [12] . of calcitriol, excluding unmeasured episodes of hypercalcaemia. This relatively low incidence of hyperSprague and Moe demonstrated that even lower doses of intravenous calcitriol are also effective in reducing calcaemia is probably due to the administration of calcitriol at night in conjunction with low-calcium serum PTH [13] . Theoretically the intravenous route of administration would bypass some of the direct dialysate. Schaefer et al. [20] directly compared the administration of calcitriol in the morning or late night effect of calcitriol on calcium absorption in the gut [9] , while increasing the delivered dose of calcitriol to in CAPD patients in a cross-over study. Eighty per cent of the patients developed hypercalcaemia when target organs such as the parathyroid glands. Studies in rats supported a greater effect with greater serum the calcitriol was administered in the morning, compared to 50% when it was administered at night [20] . levels [30] .
Oral calcitriol administered in large, intermittent Patients on CAPD may be more prone to the development of hypercalcaemia than patients on haemodialysis pulse doses was first evaluated as an alternative to the intravenous formulation in Japan. A study in 29 because of a net influx of calcium from dialysate to patients using standard (1.75 mmol/l ) calcium dialyshaemodialysis patients demonstrated a 41% decrease in serum PTH concentration over a 6-month period ate concentrations [26 ] . In contrast, low-calcium dialysate (0.875 mmol/l ) results in a net removal of with pulse therapy of 4.0 mg calcitriol administered orally twice weekly [17, 18] . Recent prospective, ran-calcium [32] and allows the use of higher quantities of calcium-containing phosphate binders with less inciddomized trials have directly compared pulse intravenous and pulse oral administration of calcitriol in ence of hypercalcaemia. Thus, lower-calcium dialysate should be utilized in CAPD patients receiving calcitriol. haemodialysis patients and found equal efficacy, despite peak serum levels up to 10 times greater with the Despite the use of low-calcium dialysate we still generated a net positive calcium balance, as demonintravenous administration [14] [15] [16] . In contrast, Mazzeferro found the intravenous formulation to be strated by the significant increase in total body calcium together with an increase in serum calcium concentrasuperior to the pulse oral therapy, but used lower doses of calcitriol and had a rise in serum calcium only tion from baseline to end-point. Unfortunately, the measurement of total body calcium does not differenin the intravenous group [31]. Thus, in haemodialysis patients, intravenous and pulse oral calcitriol are tiate between soft-tissue and bone calcium, and no increase in bone density was observed. Therefore it is equally effective in suppressing parathyroid hormone, providing a similar rise in serum calcium is observed. possible that some of the observed increase in total
